Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development.

Abstract

ABSTRACT:

Several formulations of intravaginal oestrogen are available for the treatment of genitourinary syndrome of menopause (GSM). These are safe and effective treatments for the symptoms of GSM. Licensed doses of intravaginal oestrogen do not elevate systemic estradiol levels above the normal postmenopausal range with long term use and there is no evidence of an increased risk of coronary heart disease, stroke, thromboembolism, colorectal cancer, endometrial cancer, breast cancer or breast cancer recurrence with their use. This should reassure both women and their healthcare professionals and should lead to more women receiving these localised, vaginally administered hormonal treatments. Available evidence also suggests a positive safety profile for transdermal testosterone treatment when delivered at physiological concentrations.

• Authors: Abbie J Laing, Louise Newson, James A Simon
• Journal: Cancer journal (Sudbury, Mass.) (Cancer J) 2022 May-Jun 01 Vol. 28 Issue 3 Pg. 196-203 ISSN: 1540-336X [Electronic] United States
• PMID: 35594467 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Chemical References

• Estrogens
• Testosterone

Topics

• Estrogens (adverse effects)
• Female
• Humans
• Menopause
• Neoplasm Recurrence, Local
• Risk Assessment
• Syndrome
• Testosterone (adverse effects)